Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients
Sponsor: Myriad Genetic Laboratories, Inc.
Listed as NCT01954004, this observational or N/A phase trial focuses on Prostate Cancer and remains completed. Sponsored by Myriad Genetic Laboratories, Inc., it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Myriad Genetic Laboratories, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .